Related Experiment Video
Updated: Jun 6, 2025
Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Establishment and characterization of the novel myxofibrosarcoma cell line, SMU-MFS
Naoya Nakahashi1,2, Makoto Emori3, Kohichi Takada4
1Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, West 16, South 1, Chuo-ku, Sapporo, 060-8543, Japan.
Abstract:
Myxofibrosarcoma (MFS) is one of the most common soft-tissue sarcomas in elderly patients. Owing to the limited efficacy of chemotherapy and radiotherapy, complete resection is the only available curative treatment. Therefore, developing novel therapies for MFS is important to improve clinical outcomes. Herein, a novel MFS cell line, namely SMU-MFS, was established to better understand the biologic characteristics of MFS and develop new therapies. A tissue sample from the surgically resected tumor tissue of a 56-year-old patient with a tumor was subjected to primary culture. The cell line was established and authenticated by assessing the short tandem repeats of DNA microsatellites. The monolayer cultures of SMU-MFS cells exhibited constant growth, spheroid formation, and invasive capacity. Furthermore, the cells exhibited low chemosensitivity to doxorubicin, eribulin, and pazopanib, which are used to inhibit metastatic progression. In addition, of the four mice inoculated with SMU-MFS cells, tumors developed in two mice after 8 weeks. Altogether, the findings of this study suggest that the SMU-MFS cell line can be a useful tool for investigating MFS development and evaluating novel therapeutic agents.
Insights
A new Myxofibrosarcoma (MFS) cell line, SMU-MFS, was developed for studying this elderly soft-tissue sarcoma. This cell line shows promise for investigating MFS biology and testing novel therapeutic strategies.
Area of Science:
- Oncology
- Cell Biology
- Sarcoma Research
Background:
- Myxofibrosarcoma (MFS) is a common soft-tissue sarcoma in the elderly.
- Current treatments like chemotherapy and radiotherapy have limited efficacy.
- Complete surgical resection remains the primary curative option, highlighting the need for novel therapies.
Purpose of the Study:
- To establish and characterize a novel cell line for Myxofibrosarcoma research.
- To facilitate a better understanding of MFS biologic characteristics.
- To provide a tool for evaluating new therapeutic agents for MFS.
Main Methods:
- Established a new cell line (SMU-MFS) from patient tumor tissue.
- Authenticated the cell line using DNA microsatellite analysis (short tandem repeats).
- Assessed cell growth, spheroid formation, invasiveness, and chemosensitivity in vitro, and tumor development in vivo.
Main Results:
- The SMU-MFS cell line demonstrated consistent growth, spheroid formation, and invasive capacity.
- Exhibited low sensitivity to common chemotherapeutic agents (doxorubicin, eribulin, pazopanib).
- Induced tumor formation in mice, confirming its utility in preclinical models.
Conclusions:
- The novel SMU-MFS cell line is a valuable tool for MFS research.
- It can aid in understanding MFS development and progression.
- This cell line will be instrumental in evaluating the efficacy of novel therapeutic agents.
